Q-omics provides the consensus-scored RPSAP52 profile across patient tissues and cancer cell-line models. RPSAP52 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPSAP52 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, RPSAP52 RNA expression shows 16,890 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, HNSC, and TGCT as cancer lineages where RPSAP52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPSAP52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPSAP52 survival associations across molecular data types. RPSAP52 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPSAP52 RNA expression–survival associations across cancer types. High RPSAP52 expression shows unfavorable associations in ACC, KIRC, PAAD, HNSC, LUSC and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPSAP52 RNA expression.
This table summarizes RPSAP52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPSAP52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPSAP52 shows higher tumor expression in HNSC, THCA, COAD, BLCA, LUAD and STAD. The HNSC box plot shows higher RPSAP52 RNA expression in tumor versus normal tissue (log2 FC = +1.394, t-test p < 0.001).
This table shows molecular features associated with RPSAP52 in patient tissues and cancer cell lines. In patient samples, RPSAP52 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
